Ventilatory Settings and Monitoring Variables Associated With Weaning Failure in Critically Ill Patients (WEAN-FAIL)

March 12, 2025 updated by: EMILIO MARTIN STEINBERG, Hospital Italiano de Buenos Aires

Ventilatory Settings and Monitoring Variables Associated With Weaning Failure in Critically Ill Patients: A Retrospective Study

Mechanical ventilation (MV) is essential in managing acute respiratory failure. Its duration is a crucial aspect since both, unnecessary prolongation and premature withdrawal have deleterious effects on patient outcomes in the ICU. The process of weaning refers to the set of procedures and evaluations carried out to discontinue MV. Regardless of the definition used, within the population undergoing weaning, there is a group of patients who successfully pass the daily screening but fail the spontaneous breathing trial (SBT) or the separate attempt (SA). In Argentina, this figure is 39.5%, and 31.4% in patients with COVID-19. On the other hand, another group of patients successfully passes the SA, is extubated, but fails in post-extubation. This failure rate varies in the literature, ranging from approximately 10 to 20%. In our country, this figure is 16% in the general population and rises to 29.7% in COVID-19 patients. Additionally, this population is divided into those who cannot tolerate ventilation without an artificial airway due to upper airway patency issues (such as laryngeal edema), i.e., "airway failure," and those who experience acute respiratory failure. In 2023, the WEAN SAFE study reported novel findings regarding variables associated with weaning failure. In multivariable analysis, it was found that the MV settings and monitoring variables at the time of the first SBT - respiratory rate, positive end-expiratory pressure (PEEP), dynamic airway pressure difference (peak pressure (Ppeak) minus PEEP) on the day of the SA - were associated with weaning failure. In this context, the investigators will conduct a retrospective cohort study, whose primary objective will be to assess which MV settings and monitoring variables are associated with weaning failure.

**Primary Objective** To determine if there are any MV settings or monitoring variables that are associated with extubation failure.

**Secondary Objective** To determine if there are any MV settings or monitoring variables that are associated with failure in the first SBT.

Study Overview

Study Type

Observational

Enrollment (Estimated)

1077

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

      • Ciudad Autónoma de Buenos Aires, Argentina, 1199
        • Recruiting
        • Hospital Italiano de Buenos Aires
        • Contact:
        • Sub-Investigator:
          • Mariano Setten, RT
        • Sub-Investigator:
          • Luis I Garegnani, RT
        • Sub-Investigator:
          • Damián E Steinberg, RT

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Probability Sample

Study Population

Critically ill patients who required MV and underwent a weaning process in the ICU admitted up to July 1, 2024, whose MV settings and monitoring data are complete in their medical records.

Description

Inclusion Criteria:

  • Over 18 years
  • MV for at least 48 hours, regardless of the cause of onset
  • Undergone at least one extubation, regardless of the outcome
  • At least one spontaneous breathing trial (SBT) during their ICU stay, regardless of the outcome

Exclusion Criteria:

  • MV records containing incorrect or inconsistent data
  • did not have adequate or continuous monitoring during the weaning process

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Mechanically ventilated patients

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Number of participants with extubation failure
Time Frame: 7 days
Need for reintubation within the first 7 days after the removal of the endotracheal tube, regardless of the cause that precipitates it.
7 days
Cause of reintubation
Time Frame: 7 days
Reason that precipitates the need for reinsertion of the endotracheal tube.
7 days

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Spontaneous breathing trial failure
Time Frame: Immediately after spontaneous breathing trial
Rate of restoring invasive MV due to objective or subjective signs.
Immediately after spontaneous breathing trial

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

December 1, 2024

Primary Completion (Estimated)

October 1, 2025

Study Completion (Estimated)

August 1, 2026

Study Registration Dates

First Submitted

November 8, 2024

First Submitted That Met QC Criteria

November 8, 2024

First Posted (Actual)

November 12, 2024

Study Record Updates

Last Update Posted (Actual)

March 25, 2025

Last Update Submitted That Met QC Criteria

March 12, 2025

Last Verified

March 1, 2025

More Information

Terms related to this study

Other Study ID Numbers

  • 7221

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe